share_log

Needham Reiterates Buy on Heron Therapeutics, Maintains $5 Price Target

Benzinga ·  Aug 7, 2024 10:21  · Ratings

Needham analyst Serge Belanger reiterates Heron Therapeutics (NASDAQ:HRTX) with a Buy and maintains $5 price target.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Comment Comment · Views 222

Recommended

Write a comment